MALVERN, Pa., July 31, 2012 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL), a specialty biopharmaceutical company, today announced financial results for the quarter ending on June 30, 2012. The Company also highlighted recent commercial, regulatory and clinical development progress in the second quarter of 2012 and has updated financial guidance for full year 2012.
For the quarter ended June 30, 2012, Auxilium reported net revenues of $78.2 million, compared to net revenues of $65.9 million in the second quarter of 2011, an increase of 19%. For the second quarter of 2012, U.S. Testim® and XIAFLEX® net revenues increased by 26% and 21% respectively over the comparable 2011 period. Auxilium reported net income of $7.7 million, or $0.16 per share (basic and fully diluted basis), compared to a net loss of ($5.1) million, or ($0.11) per share, reported for the second quarter of 2011.
"In the second quarter of 2012, Auxilium achieved strong growth, record net revenues, and, in addition to turning a quarterly net profit for the first time, we now expect 2012 to be our first profitable year," said Adrian Adams, Chief Executive Officer and President of Auxilium. "For the remainder of 2012 and beyond, we will continue to focus on delivering excellence in commercial execution and we anticipate a positive additional impact from GlaxoSmithKline's efforts on Testim's growth. We also look forward to filing the sBLA for XIAFLEX for the treatment of Peyronie's disease by the end of the year as we seek to obtain FDA approval for this indication."
Second Quarter 2012 and Recent Highlights:
|SOURCE Auxilium Pharmaceuticals, Inc.|
Copyright©2012 PR Newswire.
All rights reserved